Non-Small Cell Lung Cancer Therapeutics Market Report, 2015-2023

Non-small Cell Lung Cancer Therapeutics Market - An Overview

Non-small cell lung cancer therapeutics or simply NSCLC in short is a form of cancer treatment, which has seen a significant increase around the world, recently. NSCLC therapeutics initially targets the cancer type from the first stage until the last one. Rising awareness due to many government undertakings helping enhance the non-small lung cancer therapeutics market worldwide. Non-small lung type accounts for close to 90% of various types of cancers.

NSCLC therapeutics are specifically developed from a combination of advanced proteins and simple chemistry. NSCLC can metastasize in the bones of human beings, which can be tough to diagnose as well as treat the disease. There have also been increasing approvals for fresh drugs and NSCLC therapeutics by the US Food and Drug Administration (FDA) and other administrative organizations. Many such bodies are investing in several research and development activities and thereby supporting the growth of the non-small cell lung cancer therapeutics market.

The non-small cell lung cancer therapeutics market has been divided into five regions globally: Latin America, North America, Europe, the Middle East & Africa, and the Asia Pacific. North America currently dominates the non-small cell lung cancer therapeutics market because of growing assistance from the US government, which has helped the overall healthcare structure.

Asia Pacific is estimated to display a promising growth rate for the non-small cell lung cancer therapeutics market in the forthcoming years of the forecast period. The reason behind the optimism for growth in this region for the non-small cell lung cancer market is the rising awareness about new cancer treatment methods, increasing expenditure on healthcare facilities in developing countries, and an increasing number of patients diagnosed with lung cancer

The angiogenesis inhibitor segment in the global non-small cell lung cancer therapeutics market is presently dominating the market worldwide and the segment is expected to be the leader in the non-small cell lung cancer therapeutics market worldwide. The reason for the domination is the rising demand for efficient and targeted therapies in both developed and developing nations such as Japan, India and US.

Global Non-Small Cell Lung Cancer Therapeutics Market – Snapshot

Non-small cell lung cancer therapeutics or NSCLC is one of the common forms of cancer treatments. This is due to the fact that NSCLC can metastasize in human bones, which can be a difficult for diagnose and treat the disease. In around 90% of the all types of lung cancer are of non-small cell lung cancer. Therapeutics for NSCLC first targets the cancer type from its first stage to its last. They are specifically designed from a blend of advanced proteins and simple chemistry. Increasing awareness because of several government initiatives are helping to boost the development of the global non-small cell lung cancer therapeutics market.

In addition to this, growing approvals for new drugs and non-small cell lung cancer therapeutics by the US FDA (Food and Drug Administration) and other authoritative bodies. Moreover, several other authoritative bodies are now funding several research and development activities and are thus lending their support for the development of the global non-small cell lung cancer therapeutics market.

A recent research report published by Transparency Market Research expects the global non-small cell lung cancer therapeutics market to exhibit a massive CAGR of 12.1% for the given forecast period of 2015 to 2023. This growth rate will take the market to a valuation worth US$15.1 bn by the end of 2023. Initially, the global non-small cell lung cancer therapeutics market was valued at US$4.9 bn in the year 2014.

Angiogenesis Inhibitor Segment to Show Most Growth Potential in Coming Years

In terms of pipeline, the global non-small cell lung cancer therapeutics market can be segmented in early stage (phase I and II) and late stage (phase III). In terms of class of drugs, the global market is further segmented into PD-1/PD-L1 inhibitor, kinase inhibitor, microtubule stabilizer, EGFR inhibitor, folate antimetabolites, and angiogenesis inhibitors. Of these, the segment of angiogenesis inhibitor is currently dominating the global market. This particular segment is projected to continue its domination in the global market for non-small cell lung cancer therapeutics over the course of the given period of assessment. The growth of the segment is mainly attributed to the increasing demand for highly effective and more targeted therapies in both established as well as emerging economies such as the US, India, Japan, and Europe among others. With such growing demand, the angiogenesis inhibitor segment of the non-small cell lung cancer therapeutics market is expected to exhibit a CAGR of 1.8% for the period of 2015 to 2023. With this growth rate, the segment is expected to reach a valuation worth US$2,020.4 mn by the fall of 2023.

Asia Pacific to Exhibit Promising Rate of Growth in Near Future

In terms of regional segmentation, the global non-small cell lung cancer therapeutics market has five major regions namely, North America, Latin America, Asia Pacific, Europe, and the Rest of the World. Among these, the regional segment of North America is currently dominating the international market because of the increasing support from the federal government in the US for enhancing the overall healthcare infrastructure. On the other hand, Asia Pacific segment is projected to show a promising rate of growth in the next few years of the forecast period. This growth is mainly attributed to the growing number of patient base suffering from lung cancer, increasing awareness about the availability of new treatment methods of cancer, and increasing spending on healthcare infrastructure in the emerging countries.

The vendor landscape of the global non-small cell lung cancer therapeutics market is a fragmented one because of the presence of numerous leading companies. Some of the most prominent brands in the global market are AstraZeneca Plc., Pfizer Inc., Eli Lilly and Company, Boehringer Ingelheim, Squibb, and Bristol Myers among others.